Roth views divestiture as ‘essentially found money’ for Biofrontera

Roth Capital keeps a Buy rating on Biofrontera (BFRI) after the company divested the U.S. license for its impetigo drug Xepi to Pelthos Therapeutics (PTHS), for up to $10M. Roth views the proceeds as “essentially found money,” given the drug’s lack of U.S. sales and promotion. The money should fund Biofrontera to profitability, the analyst tells investors in a research note.